FCH
ABUS icon

Freestone Capital Holdings’s Arbutus Biopharma ABUS Stock Holding History

Freestone Capital Holdings’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99M Hold
442,500
– – 0.06% 184
2025
Q4 		$2.13M Hold
442,500
– – 0.06% 174
2025
Q3 		$2.01M Hold
442,500
– – 0.06% 182
2025
Q2 		$1.37M Hold
442,500
– – 0.05% 201
2025
Q1 		$1.54M Hold
442,500
– – 0.06% 180
2024
Q4 		$1.45M Sell
442,500
-700
-0.2% -$2.58K 0.05% 187
2024
Q3 		$1.71M Sell
443,200
-103,052
-19% -$395K 0.06% 175
2024
Q2 		$1.69M Buy
+546,252
New +$1.64M 0.06% 175

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Freestone Capital Holdings's ABUS Position: Q1 2026 in Review

Freestone Capital Holdings held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 442,500 shares worth $1.99M. The position accounts for 0.06% of the portfolio, ranked #184.

Freestone Capital Holdings first reported a position in ABUS in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.13M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Freestone Capital Holdings held 442,500 shares of Arbutus Biopharma worth $1.99M as of Q1 2026.
  • Freestone Capital Holdings left its Arbutus Biopharma share count unchanged in Q1 2026.
  • Arbutus Biopharma made up 0.06% of Freestone Capital Holdings's portfolio in Q1 2026, its #184 holding.
  • Freestone Capital Holdings first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 8 quarters since.
  • Freestone Capital Holdings's Arbutus Biopharma position peaked at $2.13M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Freestone Capital Holdings's 13F filing for Q1 2026, filed 13 May 2026.